Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 May 30;22:520. doi: 10.1186/s12967-024-05347-9

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2024

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 16 — Nanoparticles of albumin for combined therapeutic strategies in prostate cancer. A Near-infrared (NIR) fluorescence imaging of prostate cancer in mice using HSA@IR780@DTX nanoparticles. (I) Fluorescence imagery following nanoparticle injection into prostate cancer-afflicted mice, with tumor locations marked by white arrows. (II) Fluorescence imagery of dissected major organs from mice 48 h post-injection. (III) Semiquantitative analysis of nanoparticle distribution across major organs, presented as mean ± SD (n = 3). B Employing a combination of PTT and chemotherapy in a subcutaneous tumor model. (I) Comparative analysis of thermal response in tumor-bearing mice treated with PBS, HSA@IR780 nanoparticles, and HSA@IR780@DTX nanoparticles, with results shown as mean ± SD (n = 3). (II) Tumor growth trajectories in different mouse cohorts subjected to varied treatments, with error bars denoting standard errors of the mean (n = 5). C In vivo assessment of nanoparticle therapeutic impact. (I) Comparative imagery of mice with prostate cancer pre- and post-treatment. (II) Microscopic examination of tumor tissues stained with H&E following nanoparticle treatment

(Reprinted with permission from [114])